TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Journal

Lilly and Hims & Hers: Zepbound from $299 on the Hims platform, and what it changes for tirzepatide buyers

The November 6 deal moves where Hims & Hers patients buy Zepbound, not what it costs, and it adds a pledge that covers one company only.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

On November 6, 2026, Eli Lilly and Hims & Hers announced that Hims patients can buy Zepbound from $299 a month and Foundayo from $149 at Lilly's own self-pay prices without leaving the platform, and Hims committed not to offer compounded copies of Lilly's GLP-1s. Brand prices did not fall; only the channel changed.

Answer last reviewed:

What was announced on November 6

Eli Lilly and Hims & Hers announced an agreement on November 6, 2026 that brings Zepbound (tirzepatide) and Foundayo (orforglipron) onto the Hims & Hers platform. According to the release posted on Hims & Hers' investor site, eligible patients with a prescription from a licensed provider on the platform can get "the same self-pay prices available to any patient" without leaving Hims & Hers. Self-pay pricing "starts at $149 per month for Foundayo and $299 per month for Zepbound."

The release also says Hims & Hers "has never offered access to compounded copies of Lilly's GLP-1s, and has committed not to do so in the future." The two companies say they will protect independent clinical decisions, so providers on the platform keep prescribing whatever treatment they judge right for each patient.

Reuters reported the same day that, before this deal, Hims & Hers patients could get Lilly's drugs only by leaving the site for LillyDirect, Lilly's own cash-pay channel. Reuters also reported Lilly's figure that 40% to 45% of Zepbound sales now go through self-pay channels. Novo Nordisk, which had sued Hims & Hers over compounded copies of its drugs, has sold Wegovy and Ozempic through the platform since March.

What the release does not say

The announcement leaves out several things that decide what you would actually pay:

  • No start date for ordering Lilly drugs inside the platform, and no financial terms between the companies.
  • No Zepbound format. Lilly's $299 self-pay price applies to the KwikPen or the vial, not to the single-dose pen.
  • No dispensing pharmacy.
  • No Hims & Hers membership or program fee for Zepbound or Foundayo patients. The release lists what membership includes (24/7 care team access, nutrition guidance, regular check-ins, a community) but gives no price. Hims & Hers' own weight-loss pages could not be read on November 9, 2026.
  • No mention of insurance or Medicare. This is a self-pay arrangement.

What changed and what did not

Before and after the Lilly and Hims & Hers agreement, from the November 6, 2026 release, Reuters and Lilly's Zepbound savings page (read November 9, 2026)
ItemBefore November 6After November 6
Where a Hims & Hers patient buys ZepboundLeaves the platform for LillyDirectInside the platform
Zepbound self-pay starting price$299 (2.5 mg)From $299, the same price available to any patient
Zepbound at 7.5 to 15 mg$449 with refills within 45 daysNot changed by the announcement
Foundayo self-pay starting price$149From $149
Hims & Hers and compounded copies of Lilly GLP-1sRelease says never offeredCommitted not to offer in future
Hims & Hers fee for Lilly drug patientsNot statedNot stated
Insurance or MedicareNot part of the arrangementNot mentioned

The main point: the drug price did not move. What changed is the channel. A patient who picks Hims & Hers for tirzepatide now gets a route to brand Zepbound at Lilly's list self-pay prices, not a discount.

The Zepbound self-pay prices you would pay

Lilly's Zepbound savings page (material code CMAT-26402 09/2026, read November 9, 2026) sets the self-pay card prices for a one-month KwikPen fill:

Zepbound KwikPen self-pay card prices by dose, Lilly, read November 9, 2026
DoseRefill within 45 daysRefill later than 45 days
2.5 mg$299$299
5 mg$399$399
7.5 mg$449$499
10, 12.5 or 15 mg$449$699

Two limits matter. The card allows 11 fills a calendar year, and Lilly's page states that the "card expires and savings end on 12/31/2026." Lilly has not published 2027 self-pay prices on that page, so no one can promise these figures for next year, on any platform. See our Zepbound savings card guide.

How brand self-pay compares with compounded tirzepatide

Compounded tirzepatide is made with the drug in Zepbound, but it is not the same product. It is not FDA-approved and it is not a generic. FDA's page on unapproved GLP-1 drugs (current as of October 1, 2026) says compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug." It also reports more than 730 adverse-event reports linked to compounded tirzepatide as of May 31, 2026. Our guide to whether compounded tirzepatide is legal explains how it is still sold.

On price, our tirzepatide price index of 33 compounded programs (October 15, 2026 dataset) shows an all-in lowest monthly price from $69 to $299, with a median of $149.

Monthly cost at a maintenance dose: brand self-pay (Lilly, read November 9, 2026) vs compounded index (October 15, 2026 dataset) vs Medicare Bridge
RoutePer monthGap vs Zepbound at $449
Zepbound 10–15 mg, refill later than 45 days$699+$250
Zepbound 7.5–15 mg, refills within 45 days$449$0
Compounded index, highest$280−$169
Compounded index, median$144−$305
Compounded index, lowest (with membership)$86−$363
Medicare GLP-1 Bridge copay (eligible only, KwikPen)$50−$399

Compounded prices are the programs' own, each with its read date in the index, and many bill every 28 days rather than monthly. Brand Zepbound has trial evidence behind it, including SURMOUNT-1, where the 15 mg dose produced a 20.9% average weight reduction at 72 weeks (treatment-regimen estimand). No compounded product has its own trial result, and no price buys a guaranteed outcome. Our brand vs compounded tirzepatide guide sets out the trade-off.

What the compounding pledge does and does not cover

The pledge covers one company and one category: Hims & Hers, and compounded copies of Lilly's GLP-1s. It does not change FDA's position on compounding, and it does not bind any other program. The compounded programs in our index kept publishing tirzepatide prices on their own pages when we last read them.

For you, the practical effect is narrow. If you choose Hims & Hers for tirzepatide, expect brand Zepbound at Lilly's prices, not a compounded vial. If you want compounded tirzepatide, you will be choosing among other programs, and our Hims & Hers profile will be updated as its own pages become readable.

How this fits into choosing a ranked provider

Our methodology runs five published price checks on every program: billed by the month, medication and care in one price, the same price at every dose, no membership fee on top, and a dated first-party read. Brand Zepbound bought through any platform fails the same-price-at-every-dose check by design, because Lilly's own ladder rises from $299 to $449. That is a feature of the drug's pricing, not of Hims & Hers.

The open question for Hims & Hers is the all-in number. Until its own pages show a dated price for Zepbound patients that includes any membership, we cannot place it in a like-for-like price comparison, and we will not estimate one. If you are choosing between brand Zepbound and a compounded program, compare the two all-in monthly figures at the dose you expect to reach, not the starting price.

If you have Medicare

The new arrangement is self-pay and does not mention Medicare. If you have Part D, check the Medicare GLP-1 Bridge first. From July 1, 2026 to December 31, 2027 it charges a $50 copay for a one-month supply of Foundayo, Wegovy or the Zepbound KwikPen. Medicare.gov says it "doesn't cover single-dose Zepbound vials or pens." People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible, but "your Part D plan might cover your GLP-1s." Our Medicare GLP-1 Bridge guide has the details.

What this means for you

If you already buy Zepbound from LillyDirect. At 10 mg with on-time refills you pay $449 a month, and 12 fills at that price total 12 × $449 = $5,388, assuming the price held. Moving to Hims & Hers does not lower that. It only makes sense if you value its care team enough to pay whatever program fee it charges. Ask for that fee in writing before you switch, and see our guide to switching GLP-1 providers.

If you are starting tirzepatide and comparing brand with compounded. Twelve fills of Zepbound at today's card prices, stepping from 2.5 mg to 5 mg and then 7.5 mg or higher, come to $299 + $399 + 10 × $449 = $5,188. Twelve months at the compounded index median of $149 come to $1,728, or 13 × $149 = $1,872 if the program bills every 28 days. The brand route costs $5,188 − $1,872 = $3,316 more over that period, before any platform fee. Dose steps are your clinician's decision; these figures only show how the price ladder adds up.

If a refill slips. At 10 to 15 mg, a KwikPen refill more than 45 days after the last one costs $699 instead of $449, so one late fill adds $250.

If you qualify for the Medicare Bridge. Twelve months of KwikPen copays cost 12 × $50 = $600, which is $5,188 − $600 = $4,588 less than the self-pay ladder above.

Before you pay on any platform, ask four questions: what is the total monthly price including any membership; which Zepbound format ships; what happens if a refill falls outside 45 days; and what you will pay from January 1, 2027, when Lilly's current card savings end. This site's #1 pick, NexLife, lists compounded tirzepatide at $129 month to month and $115 a month on a 12-month plan (read November 6, 2026); see its profile.

Sources

  1. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines (November 6, 2026) · Hims & Hers Health, Inc. (investor relations; joint release with Eli Lilly and Company) · read November 9, 2026
  2. Lilly to sell obesity drugs directly on Hims & Hers site (Michael Erman, November 6, 2026) · Reuters (via Yahoo Finance UK) · read November 9, 2026
  3. Zepbound coverage and savings (CMAT-26402 09/2026) · Eli Lilly and Company · read November 9, 2026
  4. Medicare GLP-1 Bridge · Medicare.gov (CMS) · read November 9, 2026
  5. Medicare GLP-1 Bridge (page modified 07/13/2026) · Centers for Medicare & Medicaid Services · read November 9, 2026
  6. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026) · U.S. Food and Drug Administration · read November 9, 2026
  7. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), N Engl J Med 2022 · New England Journal of Medicine (abstract via Europe PMC, PMID 35658024) · read November 9, 2026
  8. Tirzepatide price index (33 compounded programs, October 15, 2026 dataset) · Tirzepatide Ranked · read October 15, 2026

Questions readers actually ask

Is Zepbound cheaper through Hims & Hers now?

No. The November 6, 2026 release says eligible patients get "the same self-pay prices available to any patient," starting at $299 a month for Zepbound. Lilly's card prices are $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 to 15 mg with refills within 45 days. The release does not state any Hims & Hers program fee, so ask for the total monthly price before you order.

Does Hims & Hers sell compounded tirzepatide?

According to the joint release, Hims & Hers "has never offered access to compounded copies of Lilly's GLP-1s, and has committed not to do so in the future." Tirzepatide is Lilly's drug, so a Hims & Hers patient choosing tirzepatide should expect brand Zepbound. The pledge covers Hims & Hers only. Other programs in our price index still publish compounded tirzepatide prices on their own pages.

Does the deal change what compounded tirzepatide costs elsewhere?

Not directly. The agreement sets no price for any other program, and it does not change FDA's position that compounded drugs are not FDA-approved. In our index of 28 compounded tirzepatide programs (October 15, 2026 dataset), the all-in lowest monthly price ran from $86 to $280, with a median of $144. Check each program's current page, because prices change and many bill every 28 days.

Can I use Medicare for Zepbound through Hims & Hers?

The release does not mention Medicare or insurance; it describes self-pay purchases. Separately, Medicare's GLP-1 Bridge charges a $50 copay from July 1, 2026 to December 31, 2027 for the Zepbound KwikPen, Wegovy and Foundayo, not Zepbound vials. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible, though their Part D plan might cover a GLP-1.

What happens to Zepbound self-pay prices in 2027?

Nobody has published them yet. Lilly's Zepbound savings page, read November 9, 2026, states that the card "expires and savings end on 12/31/2026," and it allows 11 fills a calendar year. The Hims & Hers arrangement matches Lilly's self-pay prices, so whatever Lilly sets for 2027 should flow through. Ask any platform what you will pay from January 1, 2027 before prepaying.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “How Dose Escalation Changes Tirzepatide Cost.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/journal/lilly-hims-hers-zepbound-deal-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.

Comparing 0 of 4